StreetAlpha.app
Home › Stocks › KYMR

Kymera Therapeutics, Inc. (KYMR)

Healthcare
$115.31
▼ −3.42%
LAST CLOSE · NOV 20

Kymera Therapeutics develops oral medicines for immune and inflammatory diseases using targeted protein degradation. It last closed at $115.31 on Nov 20, down 3.42% on the day. The next earnings report for KYMR is expected around Tue, Jan 12, 2027. For the quarter ended Sep 2026, KYMR reported EPS of -$1.32 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 2.2% the session after earnings. Over the last 12 months KYMR insiders bought $172.5M of stock on the open market and sold $465.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is KYMR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KYMR.

Key Stats

Last 12 months
Results
Revenue
$102.2M
+133.8% vs a year ago
Net income
−$349.4M
−341.8% margin
EPS (diluted)
−$3.64
Free cash flow
−$288.9M
−282.6% margin
Valuation
Market cap
$9.8B
85.4M shares
P/E
–
No P/E while losing money
Price to sales
96.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$373.4M
At Sep 30
Shareholder equity
$1.6B
Shares outstanding
85.4M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $72.8M$72.8MFY2021FY2022: $46.8M$46.8MFY2022FY2023: $78.6M$78.6MFY2023FY2024: $47.1M$47.1MFY2024FY2025: $39.2M$39.2MFY2025

From KYMR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Jan 12
Estimated date · Time not announced
Reported EPS
-$1.32
Quarter ended Sep 2026
Year ago EPS
-$0.94
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.89Dec '24Mar 2025: -$0.82Mar '25Jun 2025: -$0.95Jun '25Sep 2025: -$0.94Sep '25Dec 2025: -$0.98Dec '25Mar 2026: -$0.71Mar '26Jun 2026: -$0.62Jun '26Sep 2026: -$1.32Sep '26Latest -$1.32
Revenue by quarter
Dec 2024: $7.4MDec '24Mar 2025: $22.1MMar '25Jun 2025: $11.5MJun '25Sep 2025: $2.8MSep '25Dec 2025: $2.9MDec '25Mar 2026: $34.4MMar '26Jun 2026: $65.0MJun '26Sep 2026: $0Sep '26Latest $0
How KYMR moved after its last 8 reports
Average move the session after a report ±2.2%
Oct 29, 2026Time not announced+0.1%
Aug 5, 2026Time not announced+1.0%
Apr 30, 2026Time not announced−0.5%
Feb 26, 2026Time not announced+4.8%
Jan 13, 2026Time not announced+1.4%
Nov 4, 2025Time not announced+0.3%
Aug 11, 2025Time not announced−7.2%
May 9, 2025Time not announced−2.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on KYMRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on KYMR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on KYMR

Technical Analysis

KYMR · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 9% below its 20 day and 2% below its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the Pivot S1 at $113.27, and the nearest resistance the swing high (Oct 21) at $115.75.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$142.9252 week high+23.9%
$126.1620 day average+9.4%
$118.47Pivot R1+2.7%
$117.5750 day average+2.0%
$116.43Pivot+1.0%
$115.99100 day average+0.6%
$115.75Swing high (Oct 21)+0.4%
$115.31Last close
$113.27Pivot S1−1.8%
$112.77Swing low (Sep 4)−2.2%
$100.57200 day average−12.8%
$63.6952 week low−44.8%
Indicators
RSI (14)41.06Middle of its rangeNeutral
MACD1.15Below its signal lineBearish
Stochastic8.3Near the bottom of its rangeOversold
ADX (14)25.1Trending down
Williams %R-96.8Oversold below −80, overbought above −20Oversold
CCI (20)-112.8Oversold below −100, overbought above 100Oversold
Rate of change−12.5%Change over 10 sessionsBearish
ATR (14)$6.46Typical daily range, 5.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for KYMR

What happened before

See how KYMR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow KYMR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How KYMR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for KYMRHow many large options trades hit KYMR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

KYMR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲171 buying vs 112 selling
  • ▲Held by funds +2.2 pts
  • ▲Funds holding +24
  • ●Superinvestors: 1 added, 1 cut
  • ▼Put/call 1.53 to 1.66
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding302278+8.6%
In funds' top 101113−15.4%
Held by funds115.9%113.6%+2.3 pts
New / increased51 / 12046 / 96+20.4%
Reduced / sold out85 / 2784 / 26+1.8%
Put/call ratio1.661.53+8.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KYMR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

KYMR Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$172.5M1 buy · 1 insider
Sold$465.0M42 sales · 11 insiders
57% of the selling was under pre-arranged trading plans.
2025-12 bought $172.5M2025-12 sold $40.0M2026-01 sold $374K2026-02 sold $2.9M2026-03 sold $21.3M2026-04 sold $8.4M2026-05 sold $1.6M2026-06 sold $370.6M2026-07 sold $15.6M2026-09 sold $744K2026-10 sold $3.4MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 1Nello MainolfiCEOSale plan30,000$113.80$3.4M
Sep 4Brian AdamsChief Legal OfficerSale6,371$116.83$744K
Jul 7Nello MainolfiCEOSale plan50,000$119.00$6.0M
Jul 1Nello MainolfiCEOSale plan80,000$115.29$9.2M
Jul 1Noah GoodmanChief Business OfficerSale plan3,389$114.29$387K
Jun 30Bruce N. JacobsCFOSale plan77,109$114.96$8.9M
Every insider buy and sale for KYMR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See KYMR insider trades →

From SEC Form 4 filings by KYMR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYMR is in one of them and how their past KYMR trades turned out.

KYMR in the AI portfolios
Loading…

KYMR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KYMR in an article yet. Here's the latest on the wider market.

KYMR in the news

About Kymera Therapeutics

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that develops oral medicines. It uses targeted protein degradation, a method that taps into the body's own cell recycling system to remove proteins that cause disease. Its main focus is immunology, with programs aimed at conditions such as atopic dermatitis and asthma, which are often treated with injections. Its medicines are still in clinical testing and are intended for patients with these conditions.

Headquarters
Watertown, MA